Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications

1476-4598-6-26 1476-4598 Review Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications Vaish Minal minal14@yahoo.com

Department of Biochemistry, University of Lucknow – 226007, U.P., India

Molecular Cancer 1476-4598 2007 6 1 26 http://www.molecular-cancer.com/content/6/1/26 17407576 10.1186/1476-4598-6-26 20 3 2007 02 4 2007 02 4 2007 2007 Vaish; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

For the exceptional self-renewal capacity, regulated cell proliferation and differential potential to a wide variety of cell types, the stem cells must maintain the intact genome. The cells under continuous exogenous and endogenous genotoxic stress accumulate DNA errors, drive proliferative expansion and transform into cancer stem cells with a heterogeneous population of tumor cells. These cells are a common phenomenon for the hematological malignancies and solid tumors. In response to DNA damage, the complex cellular mechanisms including cell cycle arrest, transcription induction and DNA repair are activated. The cells when exposed to cytotoxic agents, the apoptosis lead to cell death. However, the absence of repair machinery makes the cells resistant to tumor sensitizing agents and result in malignant transformation. Mismatch repair gene defects are recently identified in hematopoietic malignancies, leukemia and lymphoma cell lines. This review emphasizes the importance of MMR systems in maintaining the stem cell functioning and its therapeutic implications in the eradication of cancer stem cells and differentiated tumor cells as well. The understanding of the biological functions of mismatch repair in the stem cells and its malignant counterparts could help in developing an effective novel therapies leaving residual non-tumorigenic population of cells resulting in potential cancer cures.

Background

Gurdon first introduced the concept of stemness state of the cells while successfully achieving the generation of all cell lineages of a living tadpole after transferring the nuclei from intestinal epithelial cells of feeding Xenopus tadpoles to activated enucleated eggs 12. These types of cells were later on characterized as indispensable entities, identified in multicellular organisms. The stem cell phenotype is contributed by the unique features that include (1) self-renewal which means that after cell division, one of the daughter cells must have the same genetic material as that of the parent cell, (2) differentiation i.e. capability to differentiate into multiple lineages and (3) extensive proliferation. The adult stem cells are identified in variety of tissues and organs in humans including – bone marrow, brain, skin/hair follicles, heart, lung, intestine, liver, pancreas, mammary glands, ovaries, prostrate, and testis 3.

The multipotency of stem cells to maintain tissue homeostasis and its differentiation into mature cell types is under a tightly controlled system and is associated with restricted expression profile. The expression of transport proteins – ABC (ATP-binding cassette) transporter proteins and multidrug resistant proteins that protect cells against toxins and are associated with the efflux of xenobiotic toxins, low rate of cell division and active DNA repair are the innate properties of normal development of stem cells. Besides hormonal stimulation, DNA damage is one of the key factors for stem cell activation. DNA accumulates errors either from environmental factors, which could be the exposure to radiation, chemicals or drugs, viruses and bacteria or DNA replication errors 4. This would result in complex cellular responses that include loss of cell cycle regulation, transcription induction and DNA repair mechanisms for maintaining genomic and chromosomal stability. But in absence of efficient DNA repair machinery, the stem cells accumulate harmful mutations and become resistant to apoptosis resulting in the loss of genome or instability, which ultimately lead to malignant transformation of stem cells 5. Table 1 features the stem cell activation types, which transforms them into different cancer types 46. Each stem cell activation type is exemplified with a single cancer type in the Table 1, however many could be associated. The progenitor cells also known as transit – amplifying cells arise from normal stem cells have replicative ability but not self-renewal capacity. Mutations in these progenitor cells help in regaining self-renewal property and become cancerous (Fig 1).

Table 1

Stem cell activation types transforming normal stem cells into cancerous stem cells

Stem cell activation type

Target tissue/organ

Cancer type

Naturally activated stem cell: Inactivation of RB1 gene

Retinoblasts

Retinoblastoma

Loss of tumor suppressor genes (p53)

Breast

Expression of oncogenes (ras, myc)

Brain

Hormonal stimulation: estrogen

Breast

Inflammation: Crohn disease, inflammatory bowl disease, result in activated cell growth

Colon

Viral infection: Hepatitis B and C cause inflammation and extensive cirrhosis

Liver

Exposure to irritants like tobacco, asbestos cause inflammation

Lung

Bacterial infection: Helicobacter pylori and metal dust exposure cause inflammation

Stomach

Loss of miRNA genes (miR15 and miR16) which act as tumor suppressors

Bone marrow

Chronic lymphoid leukemia

Enforced expression of miR17-92 cluster which acts as oncogenes

Bone marrow

B cell lymphoma

DNA methylation at 5-position at cytosine residue within CpGs by Dnmt1 (maintenance methyltranferase), Dnmt3a, 3b (initiate de novo methylation), Dnmt2

Colon

Colorectal

Methylation dependent repression of transcription by binding of methyl CpG binding proteins- MECP2, MBD1-4, Kaiso to DNA

Colon

Colorectal

Histone methylation by H3K4 Mtases, H3K9 Mtases, Suv39h1/Suv39h2, G9a, Eu-H Matse1, ESET/SETDB1

Prostate

Histone acetylation via histone acetyltransferases (HAT) include Gcn5 family proteins, MYST protein, p300/CBP, TAF250, ACTR/SRC1 nuclear receptor cofactors mediate transcriptional activation

Breast

Histone deacetylation silences gene expression via HDAC I family, HDAC II family, Sirtuin family (Sir2)

Bone marrow

Acute myeloid leukemia

Blockage of DNA accessibility to transcription factors by polycomb group proteins which include Polycomb repressive complexes – PRC1 contains Cbx, Mph, Ring, Bmi-1, Mel18 and PRC2 contains Ezh2, Suz12 and Eed

Bone marrow

B and T cell lymphoma

Alteration in chromatin accessibility to proteins and restriction endonucleases by the disruption of association of histones with DNA using the energy by ATP hydrolysis via ATP dependent remodeling complexes (SWI2/SNF2 protein, ISWI enzymes, Mi-2/NuRD proteins

Bone marrow

Acute myeloid leukemia

Figure 1

Development of cancer stem cells from the normal stem cells and progenitor cells

Development of cancer stem cells from the normal stem cells and progenitor cells. Accumulation of DNA errors in normal stem cells or progenitor cells are activated to generate a cancer stem cells (CSCs) that further generate a primary tumor constituting CSCs and other tumor cells.

Cancer stem cells (CSCs) were first identified in 1990s in hematological malignancies, mainly acute myelogenous leukemia (AML) and also in other subtypes like AML M0, M1, M2, M4 and M5 and chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and multiple myeloma 7. CSCs are also known in solid tumors like breast, brain, lung, prostrate, testis, ovary, stomach, colon, skin, liver, pancreas 8910. These tumor cells have a self-renewal property but undergo aberrant differentiation and constitute the heterogeneous population of tumor cells 11.

In the hematopoietic and solid tumors side population (SP) containing CSCs constitute the fraction of total population of cells that shows that CSCs is a common phenomenon for all the malignancies. SP can be identified by the efflux of fluorescent dyes by ABC transporter proteins which are the major multidrug resistant genes. In the absence of DNA repair capacity, the drug resistant pluoripotent cells accumulate mutations and show increased cell survival 12.

DNA repair

To maintain the genomic integrity and normal functioning of stem cells, several DNA repair pathways come into interplay and provide the robust defense to the cell. Absence of these repair processes have a great impact on the diminution of stem cells and increased chance for stem cell differentiation and malignant transformation due to altered gene expression.

(a) O6- alkylguanine DNA alkyl transferase (AGT) repair

AGT repair is a DNA repair protein encoded by MGMT (O6-methylguanine DNA methyltransferase) removes DNA adducts from O6 methylguanine. The failure in the repair system results in G to A transition and DNA strand break observed in hematopoietic tumors, breast, ovarian and retinoblastomas 1314.

(b) Nucleotide Excision Repair (NER)

In NER, the damaged DNA bases are recognized by XPC (xeroderma pigmentosum complementation group C) and RAD23B whereas XPA, RPA (replication protein A), RNA polymerase II transcription factor 11A and XPG excise the fragment of 27–30 nucleotides surrounding the damaged bases. The gap is further restored by DNA polymerases and ligases and replaces it with the correct sequence. Defective NER leads to xeroderma pigmentosum (skin cancer) 15.

It comprises of short and long patch pathways where DNA glycosylases generate apurinic/apyrimidinic (AP) followed by its 5' excision by AP endonucleases (APE-1) and remove damaged bases. Double-stranded breaks have the potential to be the most disruptive form of DNA damage 1617.

(d) Non-Homologous DNA End-Joining (NHEJ) repair

Double-stranded breaks have the potential to be the most disruptive form of DNA damage. The DNA double strand breaks (DSBs) produced by free radicals generated during oxidative respiration, ionizing radiation, DNA replication, malfunction of recombination activating gene complex during V(D)J (variable region, diversity region-junction region) recombination in T and B lymphocytes are brought in closed proximity by Ku70-Ku80 heterodimer and kinase activity by DNA dependent protein kinase catalytic subunit (DNA-PKcs) of DNA-PK complex followed by its ligation by XRCC4-DNA ligase IV, SCID (Severe Combined Immunodeficiency) is associated with defective NHEJ repair system 15.

(e) Homologous Recombination (HR) repair

The DSBs are repaired by misalignment, deletions, and rearrangement. ATM, a PI-3 Kinase binds DNA and phosphorylates multiple proteins. BRCA1 activated by ATM (ataxia telangiectasia) facilitates BRCA2 and RAD51 binding of the overhang followed by the attraction of RAD52/RAD54 with the help of BLM/WRN proteins. The homologous recombination is facilitated by large protein complexes at the DSBs. High incidence of leukemia, breast-ovarian, Werner's and Bloom's syndrome with severe premature aging and cancer is seen in defective HR repair system 1819.

(f) Mismatch Repair (MMR)

It is a genome surveillance system in bacteria, yeast and mammals by maintaining genomic integrity. The MMR pathway is the form of DNA repair responsible for the elimination of specific mismatched and/or unmatched bases and insertion-deletion loops (IDLs) where DNA synthesis is liable to errors, either as a part of DNA replication before cell division, or as part of DNA repair (unscheduled DNA synthesis) 20. Although DNA polymerases have the ability to identify and correct their own errors, some mistakes are not identified.

Mismatch in eukaryotic DNA is recognized by two heterodimeric complexes of Mut S related proteins – MSH2/GTBP (Mut Sα) and MSH2/MSH3 (Mut Sβ) 21. Mut Sα binds to both base – base mismatches and small ID (insertion – deletion) heterologies whereas Mut Sβ plays major role in repair of larger ID mispairs 22. Presence of ATP markedly decreases the affinity of Mut Sα for an oligonucleotide heteroduplex, an effect also observed with bacterial Mut S. Hydrolysis of ATP facilitates protein – protein interactions and or sliding along with DNA 23. Recognition of mispair is followed by binding of Mut Sα (MSH2/MSH3) with Mut L related proteins [MLH1/hPMS2 (PMS1 in yeast)] and converts into high molecular weight structure. It also increases the efficiency of Mut S proteins to recognize the mismatch. MLH1/MLH3 (PMS2 in humans) also forms the complex with Mut Sβ and help in repair of ID mispairs 24.

Proliferating cell nuclear antigen (PCNA) has been identified as DNA polymerase processivity factor and has a role in repair at or prior to excision steps as a strand discriminating factor 25. Bi – directional threading of DNA through hMut S heterodimer is continued till the arrest of forward movement of replication fork that occurs via an interaction with PCNA in the polymerase complex. Recently another eukaryotic mismatch repair endonuclease has been identified whose amino terminal domain is involved in binding to fully methylated DNA and carboxyl terminal region is involved in catalysis and complex formation with Mut L homologue MLH1. This protein is named as MED1 (methyl – CpG binding endonuclease 1). The properties of MED1 felicitate it to be a functional homologue of MutH 26.

DNA exonuclease and helicase unwind, nick and degrade the error – containing strand. After dissociation of MMR complex, PCNA, which still binds at the end of error containing primer strand, recruits replication complex and thus re-initiation starts with the help of DNA polymerase.

The mutations characterized by point mutations, insertions or deletions in the length of DNA microsatellite repeat sequences throughout the genome resulting in microsatellite instability (MSI) is a hallmark of defective DNA MMR system which result in malignant transformation 27.

The maintenance of MMR system decreases the error rates by 100 to 1000 fold during DNA replication. Since it has tremendous importance in the carcinogenesis, this review presents a discussion on the role of DNA mismatch repair system as a therapeutic potential in eliminating the cancer stem cells.

MMR deficiency and stem cell defects

The maintenance and longevity of stem cell phenotype is characterized by the presence of efficient MMR system, which result in accurate DNA replication, restore normal DNA after its damage and remove replication defects at microsatellite sequences by repairing the DNA polymerase slippage products.

The MMR deficiencies because of the mutations in wild type MMR allele with Msh2^-/-and Mlh2^-/-phenotype, mice develop stem cell-derived-lymphoid malignancies and all lymphoid tumors show MSI 28. The serial bone marrow transplantation assay was done to compare Msh2^-/-primary murine hematopoietic cells with wild type into lethally irradiated mice with temozolomide, a methylating agent. MMR deficiency as evident by MSI was observed in early progenitor colony forming unit (CFU) and Sca⁺Kit⁺Lin^- derived clones, which explain the alteration in growth and survival of hematopoietic stem cells and its long-term repopulation capacity because of accumulation of genomic instability 5. In another study, colonogenic survival was assayed in Msh2^-/-, Msh2^+/+, Msh2^-/+mouse embryonic stem cells following prolonged low level radiation treatment. The cells deficient in active MMR system survive promutagenic genomic insults by alkylating and oxidating agents that contribute to neoplastic transformation as in hereditary non-polyposis colorectal cancer (HNPCC) 29. The six cases of childhood leukemia are reported where patients are homozygous for MSH2, MLH1 or PMS2 loss of function mutations 30.

The loss of MMR genes directly or indirectly alters signal pathways, loss of strictly regulated expression of cytokine receptors, transcription factors and cell cycle regulation 5. Unlike normal stem cells the presence of damaged DNA does not activate p53 induced G1 cell cycle arrest and also the repair helicases XPB and XPD fail to functionally interact with p53 3132. This contributes to the loss of stem cell phenotype, a proliferative advantage and cancer stem cell formation.

The mitotic homologous recombination can result in chromosomal translocations, deletions or inversions with deleterious consequences in the adult or during development. Loss of MMR adds up an additional level of genetic instability in a form of chromosomal rearrangements commonly observed in hematological malignancies. High incidence of lymphoma is reported in Msh2 deficient mouse embryonic stem cells 33.

The Msh2 low and deficient mouse ES cells showed poor or complete elimination of repair function and demonstrated the resistance against the toxic effects of an ethylating agent, N-ethyl-N-nitrosourea (ENU). The ENU-induced mutagenicity under the fully or partially deficient conditions accelerated the lymphomagenesis 34. Toft et al., showed the increase in mutation frequency at Dlb-1 locus due to loss of Msh2 status in normal intestinal cells predispose to malignancy. The increased colonogenicity was observed in Msh2^-/-mouse ES cells after exposure to temozolomide but not cisplatin and contributed to failed repair mechanism and apoptosis in a p53 dependent manner 35.

In a study by Fink et al., Msh2^-/-mouse embryonic stem cells showed two-fold resistance to the cytotoxic effects of cisplatin as compared to wild type cells 36. On the contrary, Claij & Riele found no relation between the MMR capacity of cells and their response to cisplatin in a colonogenic assay in mouse ES cells 37. However, certain specific changes like mutated p53 38, increased recombinational repair or increased replicative bypass are collaborated with MMR deficiency in affecting the cytotoxicity of cisplatin.

Therapeutic implications of mismatch repair in cancer stem cells

In most of the malignancies CSCs constitute less than 1% of total cell population. They are in quiescent state and most of the conventional chemotherapeutic drug therapies are effective in actively dividing cells, so for complete eradication of CSCs, the therapeutic agents either should kill cells independently of the cell cycle or selectively induce cycling of cancer cells. Moreover, therapy should target pathways uniquely used by CSCs. CSCs express various drug transporter proteins which efflux the cytotoxic drugs and protect them from damage. The inhibitors to these transporters make the CSCs sensitive to chemotherapy. Since normal stem cells also express some of these transporters so non selective inhibition of these multidrug resistant genes also kill normal stem cells. The characterization of stem cells markers would help in identification of CSCs from normal stem cells have important implications in elimination of CSCs by specifically targeting the tumor cells 39. Table 2 lists the human cell surface markers in normal as well as CSCs, which are used to distinguish the two populations of cells.

Table 2

Markers expressed in normal and cancer stem cells in humans

Organ

Cancer type

Normal stem cell markers

Cancer stem cell markers

References

Hematopoietic

Leukemia

CD34⁺CD38^-Thy1^-Lin^-

[47, 48]

Breast

Mammary cancer

CD24^med

CD44⁺CD24^-/lowESA⁺Lin^-

[8, 11]

Brain

Brain tumor

CD133⁺Lin^-

CD133⁺Nestin

[49, 50]

Skin

Melanoma cancer

CD20^-CD166^-Nestin^-

CD20⁺CD166⁺Nestin+

[51, 52]

Prostate

Prostate cancer

CD133⁺α₂β₁^hi

CD44⁺α₂β₁^hiCD133⁺

[53]

Tongue, Larynx, Throat and Sinus

Head and neck squamous cell carcinoma (HNSCC)

CD44^-

CD44⁺

[54]

Pancreas

Pancreatic cancer

CD24^-CD44^-ESA^-

CD24⁺CD44⁺ESA⁺

[48]

The wild type MMR expression blocks the homologous recombination between the diverged DNA sequences throughout the genome and thus prevent the stem cell to accumulate further genetic instability. Hematological malignancies and lymphoma arise due to chromosomal rearrangements because of loss of MMR proteins 33. The efficient mismatch repair mechanisms engage the stem cells to undergo apoptosis when DNA is damaged. For example, hematopoietic stem cells show premature senescence (cellular aging) when they are exposed to ionizing radiation or busulfan 40. In response to alkylation or oxidative DNA damage, the DNA MMR machinery directly or indirectly stimulates signal transduction, transcription factors, loss of cell cycle regulation that derive cell fate decision pathways including apoptosis. The cells with damaged DNA bases undergo G2 arrest in presence of hMLH1 as well as the checkpoint kinases ATR and Chk1 41. The stress kinase p38 is activated in presence of hMLH1 and its inhibition cause cells to bypass G2 arrest 42. Cisplatin treated cells redistribute hPMS2 to the nucleus and its functional interaction with p73, a p53 related protein increases cell death 43. Functional hMSH2 and hMLH1 also activates c-Abl, one of the proteins of p73 dependent apoptosis pathway 4445. The MMR proteins allow the cisplatin-induced initiation of G1 arrest by cyclin D1 degradation 46. Defective MMR along with the mutated p53 response contributes to cisplatin resistance 38.

Most of the human cancers are identified having mismatch repair deficiency that result in defect in cell cycle and altered growth as in case of hematological malignancies. The defective MMR status in a damaged cell directly contributes to the resistant phenotype against the cytotoxic effects of chemotherapeutic drugs and thus these CSCs survive chemotherapy (Fig 2). The activation of DNA MMR system would help in inhibiting the survival mechanisms by raising the sensitivity of such cells to therapeutic drugs and reduce its tumor potential by arresting their growth. Owning to mass effect, progeny cancer cells still show the symptoms in the patients and therefore, the combinational therapy for the eradication of cancer stem cells and differentiated cells would be more effective. Antitumor treatment strategies selectively targeting the subset of tumor stem cells would be of clinical significance.

Figure 2

Active mismatch repair system in primary tumors help in the induction of cell death after chemotherapy

Active mismatch repair system in primary tumors help in the induction of cell death after chemotherapy. Primary tumors containing heterogeneous population of tumor cells along with small % of cancer stem cells (CSCs, represented by dark gray colored oval shape undergo chemotherapy. Presence of active mismatch repair induces cellular response followed by apoptosis, which lead to cell death. However, mismatch repair deficiency makes tumor cells insensitive to drug and it relapses.

Conclusion

The maintenance of genomic stability is the prime requirement for the stem cell phenotype and its normal functioning. The increased mutation rate and absence of MMR may give rise to stem cell failure, a proliferative advantage and cancer stem cells formation. The cancer stem cells having MMR deficiencies make them insensitive to the treatments against the cytotoxic agents and would increase the risk of relapse and metastasis. The importance of MMR in designing the therapeutic strategies specifically targeting the tumor cells is being explored and pursued in the clinical trials.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

The manuscript was written and finalized by the author.

The developmental capacity of nuclei taken from intestinal epithelial cells of feeding tadpoles Gurdon JB J Embryol Exp Morphol 1962 10 622 640 13951335 'Fertile' intestine nuclei Gurdon JB Uehlinger V Nature 1966 210 1240 1241 10.1038/2101240a0 5967799 Beyond tumorigenesis: cancer stem cells in metastasis Li F Tiede B Massague J Kang Y Cell Res 2007 17 1 3 14 10.1038/sj.cr.7310118 17179981 Cancer stem cells: redefining the paradigm of cancer treatment strategies Dean M Mol Interv 2006 6 3 140 8 10.1124/mi.6.3.5 16809475 Repopulating defect of mismatch repair-deficient hematopoietic stem cells Reese JS Liu L Gerson SL Blood 2003 102 5 1626 33 10.1182/blood-2002-10-3035 12730104 Unraveling the complex regulation of stem cells: implications for aging and cancer Oakley EJ Van Zant G Leukemia 2007 1 10 17167526 Implications of cancer stem cells in the treatment of cancer Pan CX Zhu W Cheng L Future Oncol 2006 2 6 723 31 10.2217/14796694.2.6.723 17155899 Self-renewal and solid tumor stem cells Al-Hajj M Clarke MF Oncogene 2004 23 43 7274 82 10.1038/sj.onc.1207947 15378087 On mammary stem cells Woodward WA Chen MS Behbod F Rosen JM J Cell Sci 2005 118 Pt 16 3585 94 10.1242/jcs.02532 16105882 Stem cells and their niches Moore KA Lemischka IR Science 2006 311 5769 1880 5 10.1126/science.1110542 16574858 Prospective identification of tumorigenic breast cancer cells Al-Hajj M Wicha MS Benito-Hernandez A Morrison SJ Clarke MF Proc Natl Acad Sci USA 2003 100 7 3983 8 153034 12629218 10.1073/pnas.0530291100 Cancer stem cells: Implications for cancer causation and therapy resistance Dean M Discovery Medicine 2005 5 78 282 Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase Shiraishi A Sakumi K Sekiguchi M Carcinogenesis 2000 21 10 1879 83 10.1093/carcin/21.10.1879 11023546 MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure Reese JS Qin X Ballas CB Sekiguchi M Gerson SL J Hematother Stem Cell Res 2001 10 1 115 23 10.1089/152581601750098354 11276365 DNA repair defects in stem cell function and aging Park Y Gerson SL Annu Rev Med 2005 56 495 508 10.1146/annurev.med.56.082103.104546 15660524 Second pathway for completion of human DNA base excision repair: reconstitution with purified proteins and requirement for DNase IV (FEN1) Klungland A Lindahl T EMBO J 1997 16 3341 48 1169950 9214649 10.1093/emboj/16.11.3341 Quality control by DNA repair Lindahl T Wood RD Science 1999 286 1897 905 10.1126/science.286.5446.1897 10583946 Regulation and mechanisms of mammalian double-strand break repair Valerie K Povirk LF Oncogene 2003 22 37 5792 812 10.1038/sj.onc.1206679 12947387 DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation Bakkenist CJ Kastan MB Nature 2003 21 6922 499 506 10.1038/nature01368 Replication errors: challenging the genome Jiricny J EMBO J 1998 17 6427 6436 1170991 9822589 10.1093/emboj/17.22.6427 Biochemistry and genetics of eukaryotic mismatch repair Kolodner R Genes Dev 1996 10 1433 1442 8666228 Microsatellite instability in yeast: dependence on repeat unit size and DNA mismatch repair genes Sia EA Kokoska RJ Dominska M Greenwell P Petes TD Mol Cell Biol 1997 17 2851 2858 232137 9111357 Mut S mediates heteroduplex loop formation by a translocation mechanism Allen DJ Makhov A Grilley M Taylor J Thresher R Modrich P Griffith JD EMBO J 1997 16 4467 4476 1170073 9250691 10.1093/emboj/16.14.4467 DNA mismatch repair genes and colorectal cancer Wheeler JMD Bodmer WF Gut 2000 47 148 153 10.1136/gut.47.1.148 10861278 ATP – dependent interaction of human mismatch repair proteins and dual role of PCNA in mismatch repair Gu L Hong Y McCulloch S Watanabe H Li GM Nuc Acids Res 1998 26 1173 1178 10.1093/nar/26.5.1173 DNA mismatch repair, microsatellite instability and cancer Vaish M Mittal B Ind J of Exp Biol 2002 40 989 994 Microsatellite instability in superficial urinary bladder tumors: A clinical significance Vaish M Mandhani A Mittal RD Mittal B BMC Urol 2005 5 1 2 545959 15647110 10.1186/1471-2490-5-2 Mouse models for human DNA mismatch-repair gene defects Wei K Kucherlapati R Edelmann W Trends Mol Med 2002 8 7 346 53 10.1016/S1471-4914(02)02359-6 12114115 Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation DeWeese TL Shipman JM Larrier NA Buckley NM Kidd LR Groopman JD Cutler RG te Riele H Nelson WG Proc Natl Acad Sci USA 1998 95 20 11915 20 21740 9751765 10.1073/pnas.95.20.11915 A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots Whiteside D McLeod R Graham G Steckley JL Booth K Somerville MJ Andrew SE Cancer Res 2002 62 2 359 62 11809679 DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways Nelson WG Kastan MB Mol Cell Biol 1994 14 3 1815 23 358539 8114714 The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway Wang XW Vermeulen W Coursen JD Gibson M Lupold SE Forrester K Xu G Elmore L Yeh H Hoeijmakers JH Harris CC Genes Dev 1996 10 10 1219 32 8675009 Genetic analysis of mouse embryonic stem cells bearing Msh3 and Msh2 single and compound mutations Abuin A Zhang H Bradley A Mol Cell Biol 2000 20 1 149 57 85070 10594017 DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis Claij N van der Wal A Dekker M Jansen L te Riele H Cancer Res 2003 63 9 2062 6 12727820 Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine Toft NJ Winton DJ Kelly J Howard LA Dekker M te Riele H Arends MJ Wyllie AH Margison GP Clarke AR Proc Natl Acad Sci USA 1999 96 7 3911 5 22394 10097137 10.1073/pnas.96.7.3911 In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair Fink D Zheng H Nebel S Norris PS Aebi S Lin TP Nehme A Christen RD Haas M MacLeod CL Howell SB Cancer Res 1997 57 10 1841 5 9157971 Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells Claij N te Riele H Oncogene 2004 23 1 260 6 10.1038/sj.onc.1207015 14712231 Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells Branch P Masson M Aquilina G Bignami M Karran P Oncogene 2000 19 28 3138 45 10.1038/sj.onc.1203668 10918568 Cancer stem cells Jordan CT Guzman ML Noble M N Engl J Med 2006 355 12 1253 61 10.1056/NEJMra061808 16990388 Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms Meng A Wang Y Brown SA Van Zant G Zhou D Exp Hematol 2003 31 12 1348 56 10.1016/j.exphem.2003.08.014 14662344 MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation Wang Y Qin J Proc Natl Acad Sci USA 2003 100 26 15387 92 307577 14657349 10.1073/pnas.2536810100 The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents Hirose Y Katayama M Stokoe D Haas-Kogan DA Berger MS Pieper RO Mol Cell Biol 2003 23 22 8306 15 262371 14585987 10.1128/MCB.23.22.8306-8315.2003 Structure and function of the components of the human DNA mismatch repair system Jascur T Boland CR Int J Cancer 2006 119 9 2030 5 10.1002/ijc.22023 16804905 Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin Nehme A Baskaran R Aebi S Fink D Nebel S Cenni B Wang JY Howell SB Christen RD Cancer Res 1997 57 15 3253 7 9242457 The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage Gong JG Costanzo A Yang HQ Melino G Kaelin WG Jr Levrero M Wang JY Nature 1999 399 6738 806 9 10.1038/21690 10391249 DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2 Lan Z Sever-Chroneos Z Strobeck MW Park CH Baskaran R Edelmann W Leone G Knudsen ES J Biol Chem 2002 277 10 8372 81 10.1074/jbc.M108906200 11726663 Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Bonnet D Dick JE Nat Med 1997 3 7 730 7 10.1038/nm0797-730 9212098 Identification of pancreatic cancer stem cells Li C Heidt DG Dalerba P Burant CF Zhang L Adsay V Wicha M Clarke MF Simeone DM Cancer Res 2007 67 3 1030 7 10.1158/0008-5472.CAN-06-2030 17283135 Direct isolation of human central nervous system stem cells Uchida N Buck DW He D Reitsma MJ Masek M Phan TV Tsukamoto AS Gage FH Weissman IL Proc Natl Acad Sci USA 2000 97 26 14720 5 18985 11121071 10.1073/pnas.97.26.14720 Identification of a cancer stem cell in human brain tumors Singh SK Clarke ID Terasaki M Bonn VE Hawkins C Squire J Dirks PB Cancer Res 2003 63 18 5821 8 14522905 A tumorigenic subpopulation with stem cell properties in melanomas Fang D Nguyen TK Leishear K Finko R Kulp AN Hotz S Van Belle PA Xu X Elder DE Herlyn M Cancer Res 2005 65 20 9328 37 10.1158/0008-5472.CAN-05-1343 16230395 Increased expression of stem cell markers in malignant melanoma Klein M Walter Wu P Bryan Zhao Shuping Wu Hong Klein-Szanto JP Andres Tahan R Steven Modern Pathology 2007 20 102 107 10.1038/modpathol.3800720 17143262 Prospective identification of tumorigenic prostate cancer stem cells Collins AT Berry PA Hyde S Stower MJ Maitland NJ Cancer Res 2005 65 10946 10951 10.1158/0008-5472.CAN-05-2018 16322242 Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma Prince ME Sivanandan R Kaczorowski A Wolf GT Kaplan MJ Dalerba P Weissman IL Clarke MF Ailles LE Proc Natl Acad Sci USA 2007 104 3 973 8 10.1073/pnas.0610117104 17210912